SABS is the ticker symbol for SAB Biotherapeutics, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks SABS with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is SABS a good stock to buy?

SABS is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/SABS.

Where does 13F Pro source SABS data?

All SAB Biotherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. SAB Biotherapeutics, Inc. files with the SEC under CIK 1833214. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

SAB Biotherapeutics, Inc.(SABS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

SAB Biotherapeutics, Inc. (SABS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SABS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), SAB Biotherapeutics, Inc. reports net income of $-22.5M, free cash flow of $-11.4M. Top institutional holders of SABS by reported 13-F value include Caligan Partners, Vivo Capital, PERCEPTIVE ADVISORS, based on the most recent SEC filings. SABS trades on the Nasdaq exchange and files with the SEC under CIK 1833214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SABS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SAB Biotherapeutics, Inc. directly from SEC EDGAR.

Net Income

$-22.5M

Free Cash Flow

$-11.4M

SABS key financials by period

SAB Biotherapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2024	10-K	$1.3M	$-34.1M	—
FY 2023	10-K	$2.2M	$-42.2M	—
FY 2022	10-K	$23.9M	$-18.7M	-121.0%
FY 2021	10-K/A	$60.9M	$-17.1M	-22.0%
FY 2020	10-K/A	$55.2M	$20.1M	37.2%

Institutions holding SABS

Institutional investors reporting a position in SAB Biotherapeutics, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
Caligan Partners	7,967,207	$31.1M	2026-06-30
Vivo Capital	7,299,909	$28.5M	2026-06-30
PERCEPTIVE ADVISORS	6,627,501	$25.8M	2026-06-30
ADAGE CAPITAL PARTNERS GP, L.L.C.	6,405,553	$25.0M	2026-06-30
RA CAPITAL MANAGEMENT, L.P.	4,401,500	$17.2M	2026-06-30
BALYASNY ASSET MANAGEMENT L.P.	3,760,439	$14.7M	2026-06-30
BlackRock	3,066,016	$12.0M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	2,972,929	$11.6M	2026-06-30
Commodore Capital	2,870,000	$11.2M	2026-06-30
MILLENNIUM MANAGEMENT	2,749,087	$10.7M	2026-06-30

SEC EDGAR: CIK 1833214 →

SAB Biotherapeutics, Inc.

SABS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.